重症肌無力（MG）：新療法、未滿足的需求和目標產品展望報告，2026 年

市場概覽

• 德國重症肌無力市場預計將從2025年的9,500萬美元成長到2035年的2億美元。
• 推動市場成長的因素如下：
• 標靶生技藥品和補體抑制劑的應用日益廣泛
• 擴大新型免疫療法的研發
• 未來的成長取決於安全性是否有所提高，以及是否有能夠持續控制疾病的治療方法。

重症肌無力（MG）的新療法及對 TPP 的深入研究

Thelansis 發布的《重症肌無力（MG）：新型療法、未滿足的需求和目標產品概況（TPP）洞察報告，2026》全面分析了該適應症的關鍵新興療法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、臨床試驗設計以及關鍵意見領袖（KOL）的見解。

重症肌無力（MG）概述

重症肌無力（MG）是自體免疫，雖然可以控制症狀，但長期副作用令人擔憂。然而，隨著兩類新型精準療法的出現，情況也發生了變化。這兩類療法針對的是驅動疾病的特定免疫機制，而非廣泛抑制免疫系統。其中一類抑制參與有害抗體循環的受體，另一類則阻斷直接傷害神經肌肉接頭的替代路徑。目前，每類療法中都有多種藥物獲批，醫生可以根據患者耐受性情況更換治療方案。此外，一些療法專門針對先前治療選擇有限的罕見抗體亞型。這些新療法通常與現有的免疫調節療法合併使用，而不是取代它們，目前針對B細胞標靶療法的研究不斷擴展。

主要亮點

• 根據預測，德國重症肌無力確診病例數將從2025年的7,567 例增加到2035年的8,099 例。
• 重症肌無力是一種罕見的自體免疫神經肌肉疾病，其特徵是肌肉無力和疲勞反覆發作。
• 儘管有多種治療方案可供選擇，但許多患者仍然無法充分控制病情，並且經常出現症狀惡化的情況。
• 目前仍有大量未被滿足的、標靶治療，能夠提供持續的症狀控制和改善生活品質。

透過對醫生和關鍵意見領袖（KOL）的調查所獲得的見解：

• 透過對關鍵意見領袖（KOL）的訪談，獲得了更多見解，進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 主要企業
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機會
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 認知程度
• 預期用途/治療方案
• 滿足主要未滿足需求的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

提及公司

• ImmunAbs Inc.
• NMD Pharma A/S
• Kyverna Therapeutics
• Amgen
• Janssen Research &Development, LLC
• UCB Biopharma SRL
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Harbour BioMed（Guangzhou）Co. Ltd.
• Argenx
• COUR Pharmaceutical Development Company, Inc.
• RemeGen Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Dianthus Therapeutics
• Cartesian Therapeutics
• Ra Pharmaceuticals, Inc.
• Clinique Neuro-Outaouais
• Kite, A Gilead Company
• Arcellx, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法 - 概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章 初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章 未滿足的需求和TPP分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL預期

第6章 監理與償付環境

第7章 附錄

Myasthenia Gravis (MG) Emerging Therapy and TPP Insights

Thelansis's "Myasthenia Gravis (MG) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Myasthenia Gravis (MG) Overview

Myasthenia gravis is an autoimmune disorder in which the immune system produces antibodies that disrupt communication between nerves and muscles, causing fluctuating weakness that can affect the eyes, face, throat, limbs, and, in severe cases, breathing. For decades, treatment relied heavily on broad immune suppression through corticosteroids and related agents, which controlled symptoms but carried substantial long-term side effects. That has changed with two new classes of precision therapy targeting the specific immune mechanisms driving the disease rather than suppressing the immune system broadly, one blocking a receptor responsible for recycling harmful antibodies and the other interrupting a separate pathway that damages the nerve-muscle junction directly. Several agents within each class are now approved, giving physicians the ability to switch options when one is not well tolerated, and some therapies specifically address a less common antibody subtype that previously had fewer treatment options. These newer therapies are generally used alongside, rather than replacing, established immune-modulating treatment, with research now expanding toward B-cell targeted approaches.

Key Highlights

• In Germany, diagnosed Myasthenia Gravis cases are projected to increase from 7,567 in 2025 to 8,099 by 2035.
• Myasthenia Gravis is a rare autoimmune neuromuscular disorder causing fluctuating muscle weakness and fatigue.
• Despite available therapies, many patients continue to experience inadequate disease control and frequent exacerbations.
• Significant unmet need remains for targeted therapies that provide sustained symptom control and improved quality of life.

Market Overview

• The Germany Myasthenia Gravis market is projected to grow from $95M in 2025 to $200M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologics and complement inhibitors
• Expanding development of novel immunotherapies
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• ImmunAbs Inc.
• NMD Pharma A/S
• Kyverna Therapeutics
• Amgen
• Janssen Research & Development, LLC
• UCB Biopharma SRL
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Harbour BioMed (Guangzhou) Co. Ltd.
• Argenx
• COUR Pharmaceutical Development Company, Inc.
• RemeGen Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Dianthus Therapeutics
• Cartesian Therapeutics
• Ra Pharmaceuticals, Inc.
• Clinique Neuro-Outaouais
• Kite, A Gilead Company
• Arcellx, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)